Posted by Michael Wonder on 30 Apr 2020
Highlights from the 28-30 April CHMP meeting
30 April 2020 - Eight new medicines recommended for approval.
The Committee recommended granting a marketing authorisation for Enerzair breezhaler, the first triple combination therapy for the treatment of asthma which includes an optional smart electronic sensor.
The CHMP also adopted a positive opinion for Zimbus Breezhaler (indacaterol / glycopyrronium / mometasone) which is a duplicate of Enerzair Breezhaler for the treatment of asthma.
